Stratification for Rab10-pThr73 levels in idiopathic and mutation carrying PD patients may identify individuals with increased LRRK2 kinase activity who would most likely benefit from LRRK2 kinase inhibitor treatment. The gene discussed is RAB10; the disease is Parkinson disease.